Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



Dated: February 23, 2023	Boston Scientific Corporation

	By:	/s/ Daniel J. Brennan

		Daniel J. Brennan
		Executive Vice President and Chief Financial Officer
		(duly authorized officer and principal financial officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.




Dated: February 23, 2023	By:	/s/ Daniel J. Brennan

		Daniel J. Brennan
		Executive Vice President and Chief Financial Officer
		(Principal Financial Officer)




Dated: February 23, 2023	By:	/s/ Michael F. Mahoney

		Michael F. Mahoney
		Director, Chairman of the Board, President and Chief Executive Officer
		(Principal Executive Officer)




Dated: February 23, 2023	By:	/s/ Jonathan R. Monson

		Jonathan R. Monson
		Senior Vice President, Global Controller and Chief Accounting Officer
		(Principal Accounting Officer)




Dated: February 23, 2023	By:	/s/ Nelda J. Connors

		Nelda J. Connors
		Director




Dated: February 23, 2023	By:	/s/ Charles J. Dockendorff

		Charles J. Dockendorff
		Director




Dated: February 23, 2023	By:	/s/ Yoshiaki Fujimori

		Yoshiaki Fujimori
		Director




Dated: February 23, 2023	By:	/s/ Donna A. James

		Donna A. James
		Director




Dated: February 23, 2023	By:	/s/ Edward J. Ludwig

		Edward J. Ludwig
		Director




Dated: February 23, 2023	By:	/s/ David J. Roux

		David J. Roux
		Director




Dated: February 23, 2023	By:	/s/ John E. Sununu

		John E. Sununu
		Director




Dated: February 23, 2023	By:	/s/ David S. Wichmann

		David S. Wichmann
		Director




Dated: February 23, 2023	By:	/s/ Ellen M. Zane

		Ellen M. Zane
		Director

Schedule II

VALUATION AND QUALIFYING ACCOUNTS


Description (in millions)	Balance at Beginning of Year		Cumulative effect adjustment for adoption of ASU 2016-13(1)	Credit loss exposure(1)	Write-offs(2)	Balance at End of Year
Year Ended December 31, 2022:
Allowances for credit losses	$	108	n/a	35	(35)	$	109
Year Ended December 31, 2021:
Allowances for credit losses	$	105	n/a	28	(25)	$	108
Year Ended December 31, 2020:
Allowances for uncollectible accounts	$	74	10	49	(27)	$	105

(1) Following the adoption of FASB ASC Topic 326 as of January 1, 2020, we record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense.

(2) Represents actual write-offs of uncollectible accounts.

Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES